# Tocilizumab in Cardiac Transplantation

> **NCT03644667** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 385 (actual)

## Conditions studied

- Heart Transplant

## Interventions

- **BIOLOGICAL:** tocilizumab
- **BIOLOGICAL:** Placebo
- **DRUG:** Standard of Care Triple IS

## Key facts

- **NCT ID:** NCT03644667
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-20
- **Primary completion:** 2025-03-25
- **Final completion:** 2025-03-25
- **Target enrollment:** 385 (ACTUAL)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03644667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03644667, "Tocilizumab in Cardiac Transplantation". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03644667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*